{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:53:20Z","timestamp":1780959200563,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02873-0","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:38:34Z","timestamp":1752503914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of abrocitinib treatment on lesion area and pruritus in patients with atopic dermatitis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Xiao-Li","family":"Kou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Meng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"8","key":"2873_CR1","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms22084130","volume":"22","author":"J Sroka-Tomaszewska","year":"2021","unstructured":"Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2873_CR2","doi-asserted-by":"publisher","first-page":"10381","DOI":"10.3390\/ijms221910381","volume":"22","author":"L Salvati","year":"2021","unstructured":"Salvati L, Cosmi L, Annunziato F. From emollients to biologicals: targeting atopic dermatitis. Int J Mol Sci. 2021;22(19):10381.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2873_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40272-022-00499-x","volume":"24","author":"LF Eichenfield","year":"2022","unstructured":"Eichenfield LF, Stripling S, Fung S, Cha A, O\u2019Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs. 2022;24(4):293\u2013305.","journal-title":"Paediatr Drugs"},{"issue":"13","key":"2873_CR4","first-page":"224","volume":"120","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults\u2014diagnosis and treatment. Dtsch Arztebl Int. 2023;120(13):224\u201334.","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"2873_CR5","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL, Wong MM, Rayner DG, Guyatt GH, D\u00edaz Martinez JP, Ceccacci R, Zhao IX, McMullen E, Srivastava A, Wang J, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2873_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340.","journal-title":"J Allergy Clin Immunol"},{"key":"2873_CR7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2873_CR8","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"12","key":"2873_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"2873_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, Yao Z, Takahashi H, Barbarot S, Feeney C, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2873_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"2873_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"2873_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"9","key":"2873_CR14","first-page":"1127","volume":"14","author":"GG Mitroi","year":"2024","unstructured":"Mitroi GG, Mitroi GF, Ic\u0103 OM, Anghelina F, Ciolofan MS, Mitroi MR. Off-label uses of abrocitinib: review of emerging therapeutic applications beyond atopic dermatitis. Life (Basel). 2024;14(9):1127.","journal-title":"Life (Basel)"},{"issue":"6","key":"2873_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/all.16009","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024;79(6):1501\u201315.","journal-title":"Allergy"},{"issue":"1","key":"2873_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2873_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/pharmaceutics15020385","volume":"15","author":"H Iznardo","year":"2023","unstructured":"Iznardo H, Ro\u00e9 E, Serra-Baldrich E, Puig L. Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics. 2023;15(2):385.","journal-title":"Pharmaceutics"},{"issue":"5","key":"2873_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"key":"2873_CR19","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260.","journal-title":"Front Immunol"},{"issue":"2","key":"2873_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","volume":"25","author":"RW Kim","year":"2024","unstructured":"Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol. 2024;25(2):179\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"2873_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18176\/jiaci.0906","volume":"33","author":"JC Armario-Hita","year":"2023","unstructured":"Armario-Hita JC, Gal\u00e1n-Guti\u00e9rrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Updated review on treatment of atopic dermatitis. J Investig Allergol Clin Immunol. 2023;33(3):158\u201367.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"2873_CR22","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","volume":"11","author":"S Butala","year":"2023","unstructured":"Butala S, Castelo-Soccio L, Seshadri R, Simpson EL, O\u2019Shea JJ, Bieber T, Paller AS. Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations. J Allergy Clin Immunol Pract. 2023;11(5):1361\u201373.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2873_CR23","first-page":"1419","volume":"13","author":"L Lugovi\u0107-Mihi\u0107","year":"2023","unstructured":"Lugovi\u0107-Mihi\u0107 L, Me\u0161trovi\u0107-\u0160tefekov J, Poto\u010dnjak I, Cindri\u0107 T, Ili\u0107 I, Lovri\u0107 I, Skalicki L, Be\u0161li\u0107 I, Pondeljak N. Atopic dermatitis: disease features, therapeutic options, and a multidisciplinary approach. Life (Basel). 2023;13(6):1419.","journal-title":"Life (Basel)"},{"issue":"5","key":"2873_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cells13050425","volume":"13","author":"A Pareek","year":"2024","unstructured":"Pareek A, Kumari L, Pareek A, Chaudhary S, Ratan Y, Janmeda P, Chuturgoon S, Chuturgoon A. Unraveling atopic dermatitis: insights into pathophysiology, therapeutic advances, and future perspectives. Cells. 2024;13(5):425.","journal-title":"Cells"},{"issue":"3","key":"2873_CR25","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.xjidi.2023.100195","volume":"3","author":"M Kamata","year":"2023","unstructured":"Kamata M, Tada Y. Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. 2023;3(3):100195.","journal-title":"JID Innov"},{"issue":"6","key":"2873_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40257-023-00809-0","volume":"24","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Armstrong A, Blauvelt A, Reich K. Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids. Am J Clin Dermatol. 2023;24(6):913\u201325.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"2873_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Fan H, Farooqui SA, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639\u201354.","journal-title":"Am J Clin Dermatol"},{"issue":"10348","key":"2873_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"2","key":"2873_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s13555-024-01320-y","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Simpson EL, Pink AE, Weidinger S, Chan G, Biswas P, Clibborn C, G\u00fcler E. Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: a post Hoc analysis of efficacy after treatment with dupilumab in JADE DARE. Dermatol Ther (Heidelb). 2025;15(2):367\u201380.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02873-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:50:46Z","timestamp":1757235046000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02873-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2873"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02873-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"617"}}